For the current year, one estimate has moved higher over the last 30 days compared to no negative revision. As a result, the Zacks Consensus Estimate has increased 2.2%. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why? While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an inv ...

TD Cowen and Guggenheim Securities are acting as joint book-running managers for the proposed offering. Oppenheimer & Co. is acting as lead manager for the proposed offering. Ladenburg Thalmann is acting as comanager for the proposed offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to re ...

Urogen Pharma (URGN) shares soared 9.7% in the last trading session to close at $19.20. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 32.5% gain over the past four weeks. This company is expected to post quarterly loss of $0.88 per share in its upcoming report, which represents a year-over-year change of +14.6%. Revenues are expected to be $23.69 million, up 12% from the year-ago quarter. For Urogen Pharma, the consensus EPS es ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2024 Earnings Conference Call May 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Elizabeth Barrett - President & CEO Mark Schoenberg - Chief Medical Officer Don Kim - CFO Jeff Bova - Chief Commercial Officer Conference Call Participants Tara Bancroft - TD Cowen Raghuram Selvaraju - H.C. Wainwright & Co Matt Kaplan - Ladenburg Thalmann Leland Gershell - Oppenheimer Operator Good morning ladies and gentlemen. Thank you for standing by. Welcome to the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or ...

Exhibit 99.1 UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights "In 2024 to date, UroGen has made excellent progress in both our commercial business and pipeline of innovative products designed to treat urothelial and specialty cancers," said Liz Barrett, President, and Chief Executive Officer of UroGen. "The upcoming announcement of 12-month duration of response results from ENVISION will be a key c ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Conference Call March 14, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Elizabeth Barrett - President and CEO Mark Schoenberg - Chief Medical Officer Dong Kim - CFO Jeffrey Bova - Chief Commercial Officer Silvio Pacheco - VP of Market Access Conference Call Participants Tara Bancroft - TD Cowen Leland Gershell - Oppenheimer Paul Choi - Goldman Sachs Matt Kaplan - Ladenburg Thalmann Operator Good morning, ladies and gentlemen. Thank you f ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________ to ________________ Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact name of registrant as specified in its charter) (Sta ...

Exhibit 99.1 "In 2023, UroGen achieved important operational and clinical milestones, setting us up for further success in the coming years," said Liz Barrett, President, and Chief Executive Officer of UroGen. "The Phase 3 ATLAS and ENVISION trials both produced meaningful and unprecedented results underscoring the potential of UGN-102 to fundamentally change the way patients with low-grade intermediate-risk non-muscle invasive bladder cancer are treated. We look forward to reporting the 12-month duration o ...

Urogen Pharma Ltd (NASDAQ:URGN) Q3 2023 Earnings Conference Call November 14, 2023 10:00 AM ET Company Participants Vincent Perrone - Senior Director, IR Elizabeth Barrett - President, CEO & Director Mark Schoenberg - Chief Medical Officer Dong Kim - CFO Jeffrey Bova - Chief Commercial Officer Conference Call Participants Leland Gershell - Oppenheimer Raghuram Selvaraju - H.C. Wainwright & Co. Boris Peaker - TD Cowen Paul Choi - Goldman Sachs Group Operator Good morning, ladies and gentlemen, and thank you ...